Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPLORE: Neoadjuvant XELOX and Delayed TME in High-Risk Rectal Cancer
NCT03038256Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2018
- Primary completion
- Apr 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin in rectal cancer, sponsored by Peking University People's Hospital. Status: unknown.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03038256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03038256.